ArticleACS biomaterials science & engineering2026
iPSC-Derived Bronchial Airways-On-Chip for the Assessment of Cytokine Secretion Triggered by Volatile Organic Compounds.
Article in ACS biomaterials science & engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Air quality monitoring currently relies mostly on a combination of epidemiological data and classic experimental data. Our objective was to design an alternative approach for assessing air pollutant risk potential using a specialized platform capable of detecting the cumulative and indirect effects of exposure via the inhaled route. We used a bronchial airways-on-chip (BOC) that captures key physiological features of the human lung. The platform integrates our previously developed device with in vitro differentiated bronchial epithelium derived from induced pluripotent stem cells (iPSCs). This setup is capable of replicating bronchial epithelial exposure to irritants at the air-liquid interface under controlled and reproducible conditions. It comprises the first proof-of-concept design combining a BOC with iPSC-derived bronchial epithelium as an alternative approach toward potential risk assessment of inhaled pollutants. As a representative pollutant, we use benzene, a volatile organic compound (VOC). At low concentrations and short-term exposure, it is not considered acutely harmful, but long-term exposure can result in mutagenic and carcinogenic effects. As air pollutant toxicity is known to be mediated by the respiratory epithelial lining and secretion of cytokines, we demonstrate our system to be sufficiently sensitive to capture increased cytokine secretion corresponding to increasing concentrations of benzene. Of utmost relevance is our finding that a cumulative effect could be detected, only caused by prolonged exposure at low concentrations of benzene, previously shown to be nontoxic in classic short-term in vitro studies. Finally, the cumulative effect could be reversed using a commonly used asthma medication (Montelukast), further supporting the relevance of the setup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.